Abivax S.A.

LSE 0RA9
ยฃ77.20 4.90 6.78%
์˜ค๋Š˜ ์ฃผ๊ฐ€
์˜๊ตญ
์ ‘๊ทผ ๊ถŒํ•œ์„ ์–ป๋‹ค
Finrange ์ฃผ์‹ ๋“ฑ๊ธ‰์—
์ด ์š”๊ธˆ์ œ๋ฅผ ์ด์šฉํ•˜๋ฉด ์ œํ•œ ์—†์ด ์„œ๋น„์Šค๋ฅผ ์ด์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ ๋ชจ๋“  ์ •๋ณด๋ฅผ ์ด์šฉํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
์–ป๋‹ค 7์ผ ๋ฌด๋ฃŒ

๋“ฑ๊ธ‰ ํ•€ ๋ฒ”์œ„

์ƒ‰์ธ: 21.25 %
Market cap ์‹œ๊ฐ€์ด์•ก โ€“ ํšŒ์‚ฌ์˜ ๋ชจ๋“  ์ฃผ์‹ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋ฅผ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค. ์ด๋Š” ํŠน์ • ์ฃผ์‹์˜ ๊ฐ€๊ฒฉ์— ๋ฐœํ–‰ ์ฃผ์‹์ˆ˜๋ฅผ ๊ณฑํ•˜์—ฌ ๊ณ„์‚ฐ๋ฉ๋‹ˆ๋‹ค.
427.57M
EV ๊ธฐ์—… ๊ฐ€์น˜๋Š” ํšŒ์‚ฌ์˜ ์ด ๊ฐ€์น˜๋ฅผ ์ธก์ •ํ•œ ๊ฒƒ์œผ๋กœ, ์ข…์ข… ์ฃผ์‹ ์‹œ๊ฐ€์ด์•ก์— ๋Œ€ํ•œ ๋ณด๋‹ค ํฌ๊ด„์ ์ธ ๋Œ€์•ˆ์œผ๋กœ ์‚ฌ์šฉ๋ฉ๋‹ˆ๋‹ค. ๊ธฐ์—… ๊ฐ€์น˜์—๋Š” ํšŒ์‚ฌ์˜ ์‹œ๊ฐ€์ด์•ก๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ๋‹จ๊ธฐ ๋ฐ ์žฅ๊ธฐ ๋ถ€์ฑ„์™€ ํšŒ์‚ฌ ๋Œ€์ฐจ๋Œ€์กฐํ‘œ์˜ ํ˜„๊ธˆ๋„ ํฌํ•จ๋ฉ๋‹ˆ๋‹ค.
327.12M
Beta ๋ฒ ํƒ€๋Š” ๊ฐ€์žฅ ๋„๋ฆฌ ์‚ฌ์šฉ๋˜๋Š” ์œ„ํ—˜ ์ง€ํ‘œ ์ค‘ ํ•˜๋‚˜์ด๋ฉฐ ํ†ต๊ณ„์  ์ฒ™๋„์ž…๋‹ˆ๋‹ค. ๋ถ„์„๊ฐ€๋“ค์€ ์ฃผ์‹์˜ ์œ„ํ—˜ ํ”„๋กœํ•„์„ ๊ฒฐ์ •ํ•ด์•ผ ํ•  ๋•Œ ์ด ์ฒ™๋„๋ฅผ ์ž์ฃผ ์‚ฌ์šฉํ•ฉ๋‹ˆ๋‹ค.
1.42
Shares ๋ฐœํ–‰ ์ฃผ์‹์ˆ˜๋Š” ๊ธฐ๊ด€ ํˆฌ์ž์ž๊ฐ€ ๋ณด์œ ํ•œ ์ฃผ์‹ ๋ธ”๋ก๊ณผ ํšŒ์‚ฌ ๋‚ด๋ถ€์ž๊ฐ€ ์†Œ์œ ํ•œ ์ œํ•œ๋œ ์ฃผ์‹์„ ํฌํ•จํ•˜์—ฌ ํ˜„์žฌ ๋ชจ๋“  ์ฃผ์ฃผ๊ฐ€ ๋ณด์œ ํ•˜๊ณ  ์žˆ๋Š” ํšŒ์‚ฌ์˜ ์ฃผ์‹์„ ์˜๋ฏธํ•ฉ๋‹ˆ๋‹ค.
63.16M
YTD ์—ฐ์ดˆ(YTD)๋Š” ๊ธˆ๋…„ ๋˜๋Š” ํšŒ๊ณ„์—ฐ๋„์˜ ์ฒซ๋‚ ๋ถ€ํ„ฐ ํ˜„์žฌ ๋‚ ์งœ๊นŒ์ง€์˜ ๊ธฐ๊ฐ„์„ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค. ๊ทธ ์•ฝ์–ด๋Š” ์ข…์ข… ํˆฌ์ž ์ˆ˜์ต ๋ฐ ๊ฐ€๊ฒฉ ๋ณ€ํ™”์™€ ๊ฐ™์€ ๊ฐœ๋…์„ ์ˆ˜์ •ํ•ฉ๋‹ˆ๋‹ค.
1040.32 %

๋‹ค๊ฐ€์˜ค๋Š” ์ด๋ฒคํŠธ Abivax S.A.

๋ชจ๋“  ์ด๋ฒคํŠธ
์˜ˆ์ •๋œ ํ–ฅํ›„ ์ด๋ฒคํŠธ๊ฐ€ ์—†์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ์ฐจํŠธ Abivax S.A.

์ฃผ์‹๋ถ„์„ Abivax S.A.

์ง€์‹œ์ž ํšŒ์‚ฌ ์‚ฐ์—…
P/E (LTM) ์ง€๋‚œ 12๊ฐœ์›” ๋™์•ˆ ํšŒ์‚ฌ์— ๋Œ€ํ•œ ํˆฌ์ž์ž์˜ ํˆฌ์ž๊ฐ€ ๋ช‡ ๋…„ ๋™์•ˆ ์ด์ต์œผ๋กœ ๋ณด์ƒ๋˜๋Š”์ง€ ๋ณด์—ฌ์ค๋‹ˆ๋‹ค.
-1.32 14.74
P/BV (LTM) ํ˜„์žฌ ์žฅ๋ถ€๊ฐ€์น˜์— ๋Œ€ํ•œ ์ฃผ์‹์˜ ์‹œ์žฅ ๊ฐ€๊ฒฉ ๋น„์œจ์„ ํ‘œ์‹œํ•ฉ๋‹ˆ๋‹ค.
10.52 -
EV/EBITDA (LTM) ์ง€๋‚œ 12๊ฐœ์›” ๋™์•ˆ ํšŒ์‚ฌ ๊ฐ€์น˜์™€ ์„ธ์ „ EBITDA์˜ ๋น„์œจ์„ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค.
-1.10 4.31
Net Debt/EBITDA (LTM) ํšŒ์‚ฌ์˜ ๋ถ€์ฑ„ ๋น„์œจ์€ ํšŒ์‚ฌ๊ฐ€ ๋ถ€์ฑ„๋ฅผ ์ƒํ™˜ํ•˜๊ธฐ ์œ„ํ•ด ์ง€๋‚œ 12๊ฐœ์›” ๋™์•ˆ ํ˜„๊ธˆ ํ๋ฆ„์„ ์–ผ๋งˆ๋‚˜ ์˜ค๋žซ๋™์•ˆ ์šด์˜ํ•ด์•ผ ํ•˜๋Š”์ง€๋ฅผ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค.
0.34 -
ROE (LTM) ํšŒ์‚ฌ์˜ ์ฃผ์‹ ์ž๋ณธ ์‚ฌ์šฉ ํšจ์œจ์„ฑ์„ ๋ณด์—ฌ์ค๋‹ˆ๋‹ค. ์ฆ‰, ROE๋Š” ์ง€๋‚œ 12๊ฐœ์›” ๋™์•ˆ ํˆฌ์žํ•œ ์ž๋ณธ์— ๋Œ€ํ•œ ํšŒ์‚ฌ์˜ ์ˆœ์ด์ต์ด ์–ผ๋งˆ์ธ์ง€๋ฅผ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค.
-798.30 -

์—ฐ๊ฐ„ ๊ฐ€๊ฒฉ ๋ณ€๋™ Abivax S.A.

4.85ยฃ 77.20ยฃ
์ตœ์†Œ ๋งฅ์Šค

์š”์•ฝ ๋ถ„์„ Abivax S.A.

์ ‘๊ทผ ๊ถŒํ•œ์„ ์–ป๋‹ค
Finrange ์ฃผ์‹ ๋“ฑ๊ธ‰์—
์ด ์š”๊ธˆ์ œ๋ฅผ ์ด์šฉํ•˜๋ฉด ์ œํ•œ ์—†์ด ์„œ๋น„์Šค๋ฅผ ์ด์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ ๋ชจ๋“  ์ •๋ณด๋ฅผ ์ด์šฉํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
์–ป๋‹ค 7์ผ ๋ฌด๋ฃŒ

์ฃผ์ฃผ๊ตฌ์กฐ Abivax S.A.

์ˆ˜์ต ๋ฐ ์ˆœ์ด์ต Abivax S.A.

๋ชจ๋“  ๋งค๊ฐœ๋ณ€์ˆ˜

ํšŒ์‚ฌ์†Œ๊ฐœ Abivax S.A.

ABIVAX Sociรฉtรฉ Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Sociรฉtรฉ Anonyme was incorporated in 2013 and is headquartered in Paris, France.
์ฃผ์†Œ:
7-11 boulevard Haussmann, Paris, France, 75009
ํšŒ์‚ฌ ์ด๋ฆ„: Abivax S.A.
๋ฐœํ–‰์ž ํ‹ฐ์ปค: 0RA9
๊ตญ๊ฐ€: ์˜๊ตญ
๊ตํ™˜: LSE
ํ†ตํ™”: ยฃ
๋ถ€๋ฌธ: ์‚ฐ์—…์žฌ
๋Œ€์ง€: https://www.abivax.com